This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vitamins and Minerals for Children With Downs Syndrome

This study has been completed.
Information provided by:
Institute of Child Health Identifier:
First received: September 19, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted
The trial aimed to examine the effects of supplementation with antioxidants and folinic acid on the health, growth and psychomotor development of children with Down syndrome. 156 children with Trisomy 21, less than 7 months of age were recruited and randomised into four groups to receive antioxidants, folinic acid, a combination of antioxidants and folinic acid or a placebo. Blinded outcome assessment was carried out 18 months later.Blood and urine samples were also taken around 12 months of age to examine metabolic effects of supplementation.

Condition Intervention
Trisiomy 21 (Down Syndrome) Drug: Antioxidants- (Vitamins A,C,E Selenium and Zinc) Drug: Folinic acid Drug: Vitamins A,C,E Selenium and Zinc and Folinic acid. Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Institute of Child Health:


Ages Eligible for Study:   up to 7 Months   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Under 7 months of age
  • Trisomy 21
  • Live in recruitment Area-i.e. London inside M25, in West Midlands or SW England.
  • One parent speaks English

Exclusion Criteria:

  • No life threatening cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00378456

United Kingdom
Institute of Child Health
Birmingham, United Kingdom
Peninsular Medical School
Exeter, United Kingdom
Institute of Child Health, London
London, United Kingdom
Sponsors and Collaborators
Institute of Child Health
Principal Investigator: Stuart Logan Peninsular Medical School, Exeter
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00378456     History of Changes
Other Study ID Numbers: 98CH11
Study First Received: September 19, 2006
Last Updated: September 19, 2006

Additional relevant MeSH terms:
Down Syndrome
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Vitamin A
Folic Acid
Retinol palmitate
Growth Substances
Physiological Effects of Drugs
Trace Elements
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents
Antidotes processed this record on July 21, 2017